KLRA

Kailera Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · kailera.com

$25.15

Mkt Cap $3.0B

52w Low $20.87 58.2% of range 52w High $28.23

50d MA $24.42 200d MA $24.42

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity —

ROE —

P/FCF —

RSI (14) —

ATR (14) —

Beta 0.00

50d MA $24.42

200d MA $24.42

Avg Volume 2.5M

About

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promisi…

Recent Filings

8-K

Kailera Therapeutics, Inc. -- 8-K Filing

Kailera Therapeutics completed its IPO on April 20, 2026, with new restated certificates and bylaws becoming effective, establishing the governance framework for its public company operations.

Apr 20

Data updated apr 25, 2026 5:36pm · Source: massive.com